Matrix metalloproteinase-9 expression in mammary gland tumors in dogs and its relationship with prognostic factors and patient outcome

Andreia A. Santos Department of Veterinary Clinics, University of Porto, 4099-003 Porto, Portugal.
Abel Salazar Biomedical Sciences Institute and the Multidisciplinary Unit for Biomedical Research, University of Porto, 4099-003 Porto, Portugal.

Search for other papers by Andreia A. Santos in
Current site
Google Scholar
PubMed
Close
 DVM
,
Célia C. Lopes Department of Veterinary Pathology, University of Porto, 4099-003 Porto, Portugal.

Search for other papers by Célia C. Lopes in
Current site
Google Scholar
PubMed
Close
 BSc
,
Raquel M. Marques Department of Anatomy, University of Porto, 4099-003 Porto, Portugal.

Search for other papers by Raquel M. Marques in
Current site
Google Scholar
PubMed
Close
,
Irina F. Amorim Department of Veterinary Pathology, University of Porto, 4099-003 Porto, Portugal.

Search for other papers by Irina F. Amorim in
Current site
Google Scholar
PubMed
Close
 DVM
,
Maria F. Gärtner Department of Veterinary Pathology, University of Porto, 4099-003 Porto, Portugal.
Institute of Molecular Pathology and Immunology, University of Porto, 4200-465 Porto, Portugal.

Search for other papers by Maria F. Gärtner in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
, and
Augusto J. F. de Matos Abel Salazar Biomedical Sciences Institute and the Multidisciplinary Unit for Biomedical Research, University of Porto, 4099-003 Porto, Portugal.

Search for other papers by Augusto J. F. de Matos in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Abstract

Objective—To immunohistochemically evaluate matrix metalloproteinase (MMP)-9 expression in benign and malignant mammary gland tumors (MMTs) in dogs and relate expression to prognostic factors and patient outcome.

Animals—118 female dogs with naturally occurring mammary gland tumors and 8 dogs without mammary gland tumors.

Procedures—24 benign mammary gland tumors and 94 MMTs (1/affected dog) were obtained during surgical treatment; control mammary gland tissue samples were collected from unaffected dogs after euthanasia for reasons unrelated to the study. Tumors were evaluated for proliferation, invasive growth, histologic grade, and metastatic capacity; expression of MMP-9 was determined immunohistochemically, and its relationship with clinical and histologic findings was investigated. For dogs with MMTs, follow-up continued for 2 years; data were used to compute overall survival time and disease-free interval and construct survival curves.

Results—MMTs had significantly higher MMP-9 expression in stromal cells and in neo-plastic cells than did the benign neoplasms. Stromal MMP-9 expression was also higher in highly proliferative tumors and in tumors with invasive growth, high histologic grade, and metastatic capacity. Furthermore, tumors from patients with shorter overall survival times and disease-free intervals had higher expression of MMP-9 in stromal cells.

Conclusions and Clinical Relevance—In dogs with MMTs, level of MMP-9 expression by stromal cells was related to factors of poor prognosis and shorter overall survival times and disease-free intervals. These results suggested that MMP-9 produced by tumor-adjacent stromal cells contributed to MMT progression in female dogs and that assessment of MMP-9 expression may be a valuable prognostic factor.

Abstract

Objective—To immunohistochemically evaluate matrix metalloproteinase (MMP)-9 expression in benign and malignant mammary gland tumors (MMTs) in dogs and relate expression to prognostic factors and patient outcome.

Animals—118 female dogs with naturally occurring mammary gland tumors and 8 dogs without mammary gland tumors.

Procedures—24 benign mammary gland tumors and 94 MMTs (1/affected dog) were obtained during surgical treatment; control mammary gland tissue samples were collected from unaffected dogs after euthanasia for reasons unrelated to the study. Tumors were evaluated for proliferation, invasive growth, histologic grade, and metastatic capacity; expression of MMP-9 was determined immunohistochemically, and its relationship with clinical and histologic findings was investigated. For dogs with MMTs, follow-up continued for 2 years; data were used to compute overall survival time and disease-free interval and construct survival curves.

Results—MMTs had significantly higher MMP-9 expression in stromal cells and in neo-plastic cells than did the benign neoplasms. Stromal MMP-9 expression was also higher in highly proliferative tumors and in tumors with invasive growth, high histologic grade, and metastatic capacity. Furthermore, tumors from patients with shorter overall survival times and disease-free intervals had higher expression of MMP-9 in stromal cells.

Conclusions and Clinical Relevance—In dogs with MMTs, level of MMP-9 expression by stromal cells was related to factors of poor prognosis and shorter overall survival times and disease-free intervals. These results suggested that MMP-9 produced by tumor-adjacent stromal cells contributed to MMT progression in female dogs and that assessment of MMP-9 expression may be a valuable prognostic factor.

Contributor Notes

Supported by grants from the Fundação para a Ciência e Tecnologia (project SFRH/BD/42363/2007).

Address correspondence to Dr. de Matos (ajmatos@icbas.up.pt).
  • 1.

    Singer CF, Kronsteiner N, Marton E, et al. MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Breast Cancer Res Treat 2002; 72:6977.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Pupa SM, Ménard S, Forti S, et al. New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 2002; 192:259267.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Sommerville RPT, Oblander SA, Apte SS. Matrix metalloproteinases: old dogs with new tricks. Genome Biol 2003; 4:216.1216.11.

  • 4.

    Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behaviour. Ann Rev Cell Dev Biol 2001; 17:463516.

  • 5.

    Duffy MJ, Maguire TM, Hill A, et al. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000; 2:252257.

  • 6.

    Del Casar JM, González LO, Alvarez E, et al. Comparative analysis and clinical value of the expression of metalloproteinases and their inhibitors by intratumor stromal fibroblasts and those at the invasive front of the breast carcinomas. Breast Cancer Res Treat 2009; 116:3952.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Vizoso FJ, González LO, Corte MD, et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 2007; 96:903911.

  • 8.

    González LO, Corte MD, Junquera S, et al. Expression and prognostic significance of metalloproteinases and their inhibitors in luminal A and basal-like phenotypes of breast cancer. Human Pathol 2009; 40:12241233.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Lana SE, Ogilvie GK, Hansen RA, et al. Identification of matrix metalloproteinases in canine neoplastic tissue. Am J Vet Res 2000; 61:111114.

  • 10.

    Yokota H, Kumata T, Taketaba S, et al. High expression of 92 KDa type IV collagenase (matrix metalloproteinase-9) in canine mammary adenocarcinoma. Biochym Biophys Acta 2001; 1568:712.

    • Search Google Scholar
    • Export Citation
  • 11.

    Hirayama K, Yokota H, Onai R, et al. Detection of matrix metalloproteinases in canine mammary tumours: analysis by immunohistochemistry and zymography. J Comp Pathol 2002; 127:249256.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Loukopoulos P, Mungall BA, Straw RC, et al. Matrix metalloproteinase-2 and −9 involvement in canine tumors. Vet Pathol 2003; 40:382394.

  • 13.

    Kawai K, Uetsuka K, Doi K, et al. The activity of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in mammary tumors of dogs and rats. J Vet Med Sci 2006; 68:105111.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Nowak M, Madej JA, Podhorska-Okolow M, et al. Expression of extracellular matrix metalloproteinase (MMP-9), E-cadherin and proliferation-associated antigen Ki-67 and their reciprocal correlation in canine mammary adenocarcinomas. In Vivo 2008; 22:463470.

    • Search Google Scholar
    • Export Citation
  • 15.

    Vinothini G, Balachandran C, Nagini S. Evaluation of molecular markers in canine mammary tumors: correlation with histological grading. Oncol Res 2009; 18:193201.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Amălinei C, Căruntu I, Bălan RA. Biology of metalloproteinases. Rom J Morphol Embryol 2007; 48:323334.

  • 17.

    Brooks SA, Lomax-Browne HJ, Carter TM, et al. Molecular interactions in cancer cell metastasis. Acta Histochem 2010; 112:325.

  • 18.

    Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of tumor microenvironment. Cell 2010; 141:5267.

  • 19.

    Jodele S, Blavier L, Yoon JM. Modifying the soil to affect the seed: role of stromal-derived matrix metaloproteinases in cancer progression. Cancer Metastasis Rev 2006; 25:3543.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Pellikainen JM, Ropponen KM, Kataja VV, et al. Expression of matrix metalloproteinase (MMP-2) and MMP-9 in breast cancer with a special reference to activator protein-2, HER-2, and prognosis. Clin Cancer Res 2004; 10:76217628.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 21.

    Matos AJF, Lopes C, Faustino AMR, et al. MIB-1 indices according to clinico-pathological variables in canine mammary tumours: a multivariate study. Anticancer Res 2006; 26:18211826.

    • Search Google Scholar
    • Export Citation
  • 22.

    Misdorp W, Else RW, Helmén E, et al. Histological classification of the mammary tumours of the dog and the cat. In: Shulman FL, ed. World Health Organization international histological classification of tumours of domestic animals. 2nd ed. Washington DC: Armed Forces Institute of Pathology, 1999;1629.

    • Search Google Scholar
    • Export Citation
  • 23.

    Elston CW, Ellis IO. Assessment of histological grade. In: Rosen PP, ed. Rosen's breast pathology. 3rd ed. Philadelphia: Lippincott-Raven Publishers, 1998;365382.

    • Search Google Scholar
    • Export Citation
  • 24.

    Hsu S, Raine L, Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase techniques. Am J Clin Pathol 1981; 75:816821.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25.

    Santos A, Lopes C, Marques RM, et al. Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours. Vet J 2011; 189:4348.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26.

    Agresti A. Inference for contingency tables. In: Balding DJ, Bloomfield P, Cressie NAC, eds. Categorical data analysis. 2nd ed. Hoboken, NJ: Wiley, 2002;9197, 369373.

    • Search Google Scholar
    • Export Citation
  • 27.

    Klein M, Kleinbaum DG. Kaplan-Meier survival curves and the log-rank test. In: Gail M, Krickeberg K, Samet J, et al, eds. Survival analysis—a self-learning text. 2nd ed. New York: Springer, 2005;4582.

    • Search Google Scholar
    • Export Citation
  • 28.

    Köhrmann A, Kammerer U, Kapp M, et al. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer [serial online]. 2009; 9:188. Available at: www.biomedcentral.com/1471-2407/9/188. Accessed Oct 10, 2010.

    • Search Google Scholar
    • Export Citation
  • 29.

    Owen JL, Iragavarapu-Charyulu V, Gunja-Smith Z, et al. Up-regulation of matrix metalloproteinase-9 in T lymphocytes of mammary tumour bearers: role of vascular endothelial growth factor. J Immunol 2003; 171:43404351.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30.

    Tětu B, Trudel D, Wang CS. Proteases des cellules stromales réactionnelles du cancer: une cible thérapeutique attrayante. Bull Cancer 2006; 93:944948.

    • Search Google Scholar
    • Export Citation
  • 31.

    MacDougall JR, Matrisian LM. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 1995; 14:351362.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 32.

    Micke P, Östman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 2004; 45:S163S175.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 33.

    Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteinases. Amino Acids 2011; 41:271290.

  • 34.

    Kim HJ, Park C, Park BW, et al. Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast. Yonsei Med J 2006; 47:333342.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35.

    Jobim FC, Xavier NL, Uchoa DM, et al. Prevalence of vascular-endothelial growth factor, matrix metalloproteinases and tissue inhibitors of metalloproteinases in primary breast cancer. Braz J Med Biol Res 2009; 42:979987.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 36.

    Peña LL, Nieto AI, Pérez-Alenza D, et al. Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables. J Vet Diagn Invest 1998; 10:237246.

    • Crossref
    • Search Google Scholar
    • Export Citation

Advertisement